Publications

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Cell

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

06-09-2018

Annals of oncology : official journal of the European Society for Medical Oncology

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

01-07-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

01-07-2025

European journal of cancer (Oxford, England : 1990)

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

18-06-2025

Cancer cell

Learning the language of T cell receptors through large-scale screening.

09-06-2025

Nature medicine

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.

05-06-2025

European journal of cancer (Oxford, England : 1990)

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.

03-06-2025

British journal of cancer

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

01-06-2025

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities.

01-06-2025

Journal of the National Cancer Institute

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

01-06-2025

The British journal of surgery

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.

31-05-2025

EJNMMI research

Metabolic parameters on baseline and early [¹⁸F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.

28-05-2025

Trends in cancer

Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?

28-05-2025

Clinical nuclear medicine

Imaging Proliferation of Stage IV Cutaneous Melanoma With 18F-FLT PET/CT: A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?

27-05-2025

Journal of the American Medical Informatics Association : JAMIA

Multimodal integration of longitudinal noninvasive diagnostics for survival prediction in immunotherapy using deep learning.

26-05-2025

Med (New York, N.Y.)

Advances in TIL therapy: Expanding the horizons beyond melanoma.

10-05-2025

European journal of cancer (Oxford, England : 1990)

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

02-05-2025

British journal of cancer

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

29-04-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

08-04-2025

Medical decision making : an international journal of the Society for Medical Decision Making

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

01-04-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

01-04-2025

European journal of cancer (Oxford, England : 1990)

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.

11-03-2025

The oncologist

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

10-03-2025

ESMO open

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series.

01-03-2025

Nature medicine

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

01-03-2025

Transplantation and cellular therapy

Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products.

01-03-2025

European journal of cancer (Oxford, England : 1990)

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

05-02-2025

European journal of cancer (Oxford, England : 1990)

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

05-02-2025

Nature biotechnology

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

01-02-2025

Journal of cancer survivorship : research and practice

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.

01-02-2025

Journal for immunotherapy of cancer

Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

20-01-2025

Nature communications

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

14-01-2025

Immunity

Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation.

14-01-2025

The New England journal of medicine

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

02-01-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

01-01-2025

Frontiers in immunology

Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system.

24-12-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.

01-12-2024

ESMO open

Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.

01-12-2024

Gynecologic and obstetric investigation

Assisted Reproductive Technology, Pregnancy, and Recurrent Disease in Melanoma Patients: A 30-Year Single Institution Experience.

15-11-2024

JCI insight

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

08-11-2024

The New England journal of medicine

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

07-11-2024

European journal of cancer (Oxford, England : 1990)

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

01-11-2024

Nature medicine

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

01-11-2024

International journal of cancer

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

15-10-2024

ESMO open

ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology.

01-10-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

01-10-2024

Frontiers in immunology

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

11-09-2024

Oncoimmunology

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.

27-08-2024

European journal of cancer (Oxford, England : 1990)

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

01-08-2024

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Learning the language of T cell receptors through large-scale screening.

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities.

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.

Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.

Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?

Imaging Proliferation of Stage IV Cutaneous Melanoma With 18F-FLT PET/CT: A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?

Multimodal integration of longitudinal noninvasive diagnostics for survival prediction in immunotherapy using deep learning.

Advances in TIL therapy: Expanding the horizons beyond melanoma.

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series.

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products.

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.

Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation.

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system.

Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.

Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.

Assisted Reproductive Technology, Pregnancy, and Recurrent Disease in Melanoma Patients: A 30-Year Single Institution Experience.

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology.

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

This site uses cookies

Metabolic parameters on baseline and early [¹⁸F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.